Isoniazid and Multiple sclerosis relapse - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis relapse is reported as a side effect among people who take Isoniazid (isoniazid), especially for people who are female, 40-49 old, have been taking the drug for 1 - 6 months also take Gilenya, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Multiple sclerosis relapse when taking Isoniazid. It is created by eHealthMe based on reports of 19,852 people who have side effects when taking Isoniazid from the FDA, and is updated regularly.

What is Isoniazid?

Isoniazid has active ingredients of isoniazid. It is often used in tuberculosis. eHealthMe is studying from 20,174 Isoniazid users. Check the latest studies of Isoniazid.

What is Multiple sclerosis relapse?

Multiple sclerosis relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,033 drugs and 943 conditions by eHealthMe. Check the latest studies of Multiple sclerosis relapse.

On Jul, 29, 2026

19,852 people reported to have side effects when taking Isoniazid.
Among them, 11 people (0.06%) have Multiple sclerosis relapse.

Could Isoniazid cause Multiple sclerosis relapse?

Among these 11 people:

How long have people been on Isoniazid when they have Multiple sclerosis relapse? *

What is the gender of people who have Multiple sclerosis relapse when taking Isoniazid? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Multiple sclerosis relapse when taking Isoniazid? *

What are other drugs people take besides Isoniazid? *

What are other side effects people have besides Multiple sclerosis relapse? *

Weight Decreased: 3 people, 27.27%
Necrosis (the death of body tissue): 3 people, 27.27%
Acne (skin problems that cause pimples): 3 people, 27.27%
Cheilitis (infection of lips): 3 people, 27.27%
Decreased Immune Responsiveness: 3 people, 27.27%
Eye Pruritus (eye itching): 3 people, 27.27%
Face Injury: 3 people, 27.27%
Facial Paralysis (loss of function of face muscle): 3 people, 27.27%
Feeling Hot: 3 people, 27.27%
Hypoaesthesia (reduced sense of touch or sensation): 3 people, 27.27%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 7 people, 63.64%
Tuberculin Test Positive: 3 people, 27.27%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 3 people, 27.27%
Nasopharyngitis (inflammation of the nasopharynx): 3 people, 27.27%
Headache (pain in head): 3 people, 27.27%
Latent Tuberculosis (hidden tuberculosis): 2 people, 18.18%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 1 person, 9.09%
Insomnia (sleeplessness): 1 person, 9.09%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 1 person, 9.09%
Depression: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Isoniazid and have Multiple sclerosis relapse?

- Check whether Multiple sclerosis relapse is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Isoniazid:

Isoniazid (20,174 reports)

Browse all side effects of Isoniazid:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis relapse:

Multiple sclerosis relapse (1,033 drugs)

Browse all the conditions that are associated with Multiple sclerosis relapse:

Multiple sclerosis relapse (943 conditions)

Related publications that referenced our studies

Ganguly, R. J., Abraham, R. R., Prasad, R., & Rao, B. C, "Hyperglycaemia induced by isoniazid preventive therapy", Journal of Family Medicine and Primary Care, 2018 Jan .
Ganguly, R. J., Abraham, R. R., Prasad, R., & Rao, B. C, "Hyperglycaemia induced by isoniazid preventive therapy", Journal of Family Medicine and Primary Care, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on isoniazid (the active ingredients of Isoniazid) and Isoniazid (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.